A cardiologist-led think tank tracked data from more than 1 million procedures, exploring the clinical and economic impacts of implanting low-value coronary stents. 

New data presented at TCT 2023 suggest the Evoque tricuspid valve replacement system could make a significant impact on the lives of patients with severe TR. 

Intravascular lithotripsy therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1.

Michael Reardon, MD, discussed his team's late-breaking results at TCT 2023 in San Francisco. 

While it is not as well-known as some other heart-healthy diets, the portfolio diet is linked to key cardiovascular benefits. "We need to get the word out," one dietitian said. 

Fuster, one of the world's most celebrated cardiologists, currently serves as the hospital’s president and physician-in-chief.

Lawrence Faucette, the second patient to ever receive a genetically modified pig heart, died on Oct. 30. “He can never be forgotten," his wife said in a statement. 

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

Short-term mortality, however, does not appear to change when TAVR patients present with active cancer. 

Robert Yeh, MD, detailed the importance of the pivotal AGENT IDE trial, which focused on the use of a paclitaxel-coated balloon to treat in-stent restenosis.